Naomi Kitayama
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Naomi Kitayama has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Atsushi Otsuka
Department of Dermatology Kindai University Faculty of Medicine Osaka Japan
3 shared publications - Kenji Kabashima
Department of Dermatology Kyoto University Graduate School of Medicine Kyoto Japan
3 shared publications - Chisa Nakashima
Department of Dermatology, Kindai University Faculty of Medicine, 1-14-1 Mihara-dai, Minami-ku, Sakai 590-0197, Osaka, Japan
2 shared publications - Satoshi Nakamizo
Department of Dermatology Kyoto University Graduate School of Medicine Kyoto Japan
2 shared publications - Chan Kwon Jung
Department of Hospital Pathology, College of Medicine, The Catholic University of Korea, Seoul, Korea
1 shared publication - Gyohei Egawa
Department of Dermatology Kagoshima University Graduate School of Medical and Dental Sciences Kagoshima Japan
1 shared publication
Latest Publications
- 3 September 2025
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 782, 152590
Targeting PAR-2 in atopic dermatitis: Preclinical evaluation of the novel inhibitor E6795
- 3 September 2025
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 782, 152590
Targeting PAR-2 in atopic dermatitis: Preclinical evaluation of the novel inhibitor E6795
- Open Access
- 1 January 2021
- Published by Japan Endocrine Society in Endocrine Journal
- Vol. 68 (8) , 871-880
How to identify indolent thyroid tumors unlikely to recur and cause cancer death immediately after surgery—Risk stratification of papillary thyroid carcinoma in young patients—
Current histopathological diagnosis methods cannot distinguish the two types of thyroid carcinoma: clinically significant carcinomas with a potential risk of recurrence, metastasis, and cancer death, and clinically insignificant carcinomas with a slow growth rate. Both thyroid tumors are diagnosed as “carcinoma” in current pathology practice. The clinician usually recommends surgery to the patient and the patient often accepts it because of cancer terminology. The treatment for these clinically insignificant carcinomas does not benefit the patient and negatively impacts society. The author proposed risk stratification of thyroid tumors using the growth rate (Ki-67 labeling index), which accurately differentiates four prognostically relevant risk groups based on the Ki-67 labeling index, ≥30%, ≥10 and 5 and <10%, and ≤5%. Indolent thyroid tumors with an excellent prognosis have the following four features: young age, early-stage (T1-2 M0), curatively treated, and low proliferation index (Ki-67 labeling index of ≤5%), and are unlikely to recur, metastasize, or cause cancer death. Accurate identification of these indolent tumors helps clinicians select more conservative treatments to avoid unnecessary aggressive (total thyroidectomy followed by radio-active iodine) treatments. Clinicians can alleviate the fears of patients by confirming these four features, including the low proliferation rate, in a pathology report immediately after surgery when patients are most concerned.
- 1 January 2021
- Published by Japan Endocrine Society in Endocrine Journal
- Vol. 68 (8) , 871-880
Open AccessHow to identify indolent thyroid tumors unlikely to recur and cause cancer death immediately after surgery—Risk stratification of papillary thyroid carcinoma in young patients—
Current histopathological diagnosis methods cannot distinguish the two types of thyroid carcinoma: clinically significant carcinomas with a potential risk of recurrence, metastasis, and cancer death, and clinically insignificant carcinomas with a slow growth rate. Both thyroid tumors are diagnosed as “carcinoma” in current pathology practice. The clinician usually recommends surgery to the patient and the patient often accepts it because of cancer terminology. The treatment for these clinically insignificant carcinomas does not benefit the patient and negatively impacts society. The author proposed risk stratification of thyroid tumors using the growth rate (Ki-67 labeling index), which accurately differentiates four prognostically relevant risk groups based on the Ki-67 labeling index, ≥30%, ≥10 and 5 and <10%, and ≤5%. Indolent thyroid tumors with an excellent prognosis have the following four features: young age, early-stage (T1-2 M0), curatively treated, and low proliferation index (Ki-67 labeling index of ≤5%), and are unlikely to recur, metastasize, or cause cancer death. Accurate identification of these indolent tumors helps clinicians select more conservative treatments to avoid unnecessary aggressive (total thyroidectomy followed by radio-active iodine) treatments. Clinicians can alleviate the fears of patients by confirming these four features, including the low proliferation rate, in a pathology report immediately after surgery when patients are most concerned.
- 24 August 2017
- Published by Wiley in The Journal of Dermatology
- Vol. 44 (12) , e363-e364
Case of diffuse panbronchiolitis developed in a patient with epidermodysplasia verruciformis
- 24 August 2017
- Published by Wiley in The Journal of Dermatology
- Vol. 44 (12) , e363-e364
Case of diffuse panbronchiolitis developed in a patient with epidermodysplasia verruciformis